LONDON (Reuters) - GlaxoSmithKline is discussing the sale of its thrombosis drug brands Arixtra and Fraxiparine, along with a related French factory, to Aspen Pharmacare in a deal that could be worth some $1 billion.Full story
Drug manufacturer GlaxoSmithKline said Thursday it has investigated an accusation that its salespeople in China bribed doctors and found no evidence of wrongdoing. Full story
LONDON (Reuters) - GlaxoSmithKline has finally won a green light from Britain's healthcare cost agency NICE for its platelet-boosting drug Revolade, after offering a price discount to the country's state-run healthcare service. Full story
Andrew Witty, CEO of GlaxoSmithKline, discusses his company's 2012 earnings and explains why he is optimistic about the company's restructuring plans in Europe.
CNBC's David Faber reports the latest details on GlaxoSmithKline's takeover bid for Human Genome Science.
Triple digit heat follows power outages; Where homes become ovens; Inside Colorado’s burn zone; GlaxoSmithKline pays $3 billion to settle fraud case; Dual-engine failure caused jet crash; Pena Nieto promises to jumpstart Mexico’s economy; Improving firefighter safety; Statue of Liberty replica moves
A GlaxoSmithKline logo is seen outside one of its buildings in west London, February 6, 2008. REUTERS/Toby Melville/FILE PHOTO
Signage is pictured on the company headquarters of GlaxoSmithKline in west London in this July 21, 2008, file photo. GlaxoSmithKline said on June 3, 2013, that its breast cancer drug lapatinib in combination with chemotherapy did not improve survival rates for patients with gastric cancer compared t
Signage is pictured on the company headquarters of GlaxoSmithKline in west London July 21, 2008. GlaxoSmithKline announce their half yearly results on Wednesday July 23. REUTERS/Toby Melville
